1.

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.

2.

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.

3.

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.

1.

Primary immune thrombocytopenia in adults. Guidelines for diagnosis and treatment anno 2013 proposed by the Belgian Hematological Society

2.

Primary immune thrombocytopenia in adults. Guidelines for diagnosis and treatment anno 2013 proposed by the Belgian Hematological Society

3.

Primary immune thrombocytopenia in adults. Guidelines for diagnosis and treatment anno 2013 proposed by the Belgian Hematological Society

1.

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.

2.

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.

3.

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.

1.

Mutations screening in Belgium patients with haemophilia A: identification of 28 new genetic alterations and study of causal effect of 15 unreported missense mutations

2.

Mutations screening in Belgium patients with haemophilia A: identification of 28 new genetic alterations and study of causal effect of 15 unreported missense mutations

3.

Mutations screening in Belgium patients with haemophilia A: identification of 28 new genetic alterations and study of causal effect of 15 unreported missense mutations

1.

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus

1.

Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus

1.

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

2.

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

3.

Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

1.

Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus (Acta Neurologica Belgica, (2018), 118, 1, (7-11),...

1.

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM